UCLA scientists have used innovative brain-scan technology developed at UCLA, along with patient-specific information on Alzheimer's disease risk, to help diagnose brain aging, often before symptoms appear. Published in the January issue of Archives of General Psychiatry, their study may offer a more accurate method for tracking brain aging.
Researchers used positron emission tomography (PET), which allows "a window into the brain" of living people and specifically reveals plaques and tangles, the hallmarks of neurodegeneration. The PET scans were complemented by information on patients' age and congnitive status and a genetic profile.
"Combining key patient information with a brain scan may give us better predictive power in targeting those who may benefit from early interventions, as well as help test how well treatments are working," said study author Dr. Gary Small, who holds UCLA's Parlow-Solomon Chair on Aging and is a professor at the Semel Institute for Neuroscience and Human Behavior at UCLA.
Scientists took PET brain scans of 76 non-demented volunteers after they had been intravenously injected with a new chemical marker called FDDNP, which binds to plaque and tangle deposits in the brain. Researchers were then able to pinpoint where these abnormal protein deposits were accumulating.
They reported that older age correlated with higher concentrations of FDDNP in the medial and lateral temporal regions of the brain, areas involved with memory, where plaques and tangles usually collect. The average age of study volunteers was 67.
Thirty-four of the 76 volunteers carried the APOE-4 gene allele, which heightens the risk for developing Alzheimer's disease. This group demonstrated higher FDDNP levels in the frontal region of the brain, also involved in memory, than study participants without allele.
"We found that for many volunteers, the imaging scans reflected subtle brain changes, which take place before symptoms manifest," said Small, who is also director of the UCLA Center on Aging.
Small noted that the brain will try to compensate for any problems, which is why cognitive symptoms may not become apparent until much later.
"This type of scan offers an opportunity to see what is really going on in the brain," he said.
Another subset of the volunteers had mild cognitive impairment (MCI), a condition that increases the risk of developing Alzheimer's disease. These 36 volunteers had higher measures of FDDNP in the medial temporal brain regions than normal volunteers. Those who had both MCI and the APOE-4 gene had higher concentrations of FDDNP in the medial temporal brain regions than volunteers who had MCI but not APOE-4.
"We could see more advancing disease in those with mild cognitive impairment, who are already demonstrating some minimal symptoms," Small said. "Eventually, this imaging method, together with patient information like age, cognitive status and genetics, may help us better manage brain aging."
According to Small, in the future, brain aging may be controlled similarly to high cholesterol or high blood pressure. Patients would receive a brain scan and perhaps a genetic test to predict their risk. Medications and other interventions could be prescribed, if necessary, to prevent or delay future neurodegeneration, allowing doctors to protect a healthy brain before extensive damage occurs. The brain scans may also prove helpful in tracking the effectiveness of treatments.
PET, combined with the FDDNP probe, is the only imaging technology that offers a full profile of neurodegeneration that includes measures of both plaques and tangles ‹ the physical evidence of Alzheimer's disease in the brain.
"The fact that we can see tau tangles as well as amyloid plaques is critically important in early detection of brain aging, since the tangles are the first abnormal proteins that appear in the brain, long before dementia is clinically obvious to the physician," said Dr. Jorge R. Barrio, a study author and professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA.
Such subtleties allow more insight into how the plaques and tangles spread and ultimately how Alzheimer's disease may develop.
Currently, the new FDDNP-PET scans are used in a research setting, but clinical trials are in development to bring the technology to wider patient use.
Monday, February 23, 2009
Assessment Technique Lets Scientists See Brain Aging Before Symptoms Appear
Star Light, Star Bright, Its Explanation is Out of Sight
A mysterious flash of light from somewhere near or far in the universe is still keeping astronomers in the dark long after it was first detected by NASA's Hubble Space Telescope in 2006. It might represent an entirely new class of stellar phenomena that has previously gone undetected in the universe, say researchers.
Astronomers commonly observe intense flashes of light from a variety of stellar explosions and outbursts, such as novae and supernovae. Hubble discovered the cosmic flash on February 21, 2006. It steadily rose in brightness for 100 days, and then dimmed back to oblivion after another 100 days.
The rise and fall in brightness has a signature that simply has never been recorded for any other type of celestial event. Supernovae peak after no more than 70 days, and gravitational lensing events are much shorter. Therefore, this observation defies a simple explanation, reports Kyle Barbary of the Lawrence Berkeley National Laboratory (LBNL) in Berkeley, Calif. He is describing the bizarre Hubble observation at the 213th meeting of the American Astronomical Society in Long Beach, Calif. "We have never seen anything like it," he concludes.
The spectral fingerprints of light coming from the object, cataloged as SCP 06F6, also have eluded identification as being due to any specific element. One guess is that the features are redshifted molecular carbon absorption lines in a star roughly one billion light-years away.
But searches through various astronomical survey catalogs for the source of the light have not uncovered any evidence for a star or galaxy at the location of the flash. The Supernova Cosmology Project at LBNL discovered it serendipitously in a search for supernovae.
Hubble was aimed at a cluster of galaxies 8 billion light-years away in the spring constellation Bootes. But the mystery object could be anywhere in between, even in the halo of our own Milky Way galaxy.
Papers published by other researchers since the event was reported in June 2006, have suggested a bizarre zoo of possibilities: the core collapse and explosion of a carbon rich star, a collision between a white dwarf and an asteroid, or the collision of a white dwarf with a black hole.
But Barbary does not believe that any model offered so far fully explains the observations. "I don't think we really know what the discovery means until we can observe similar objects in the future."
All-sky surveys for variable phenomena, such as those to be conducted with the planned Large Synoptic Survey Telescope, may ultimately find similar transient events in the universe.
Hubble Finds Stars that Go Ballistic
Even some stars go ballistic, racing through interstellar space like bullets and tearing through clouds of gas.
Images from NASA's Hubble Space Telescope reveal 14 young, runaway stars plowing through regions of dense interstellar gas, creating brilliant arrowhead structures and trailing tails of glowing gas. These arrowheads, or bow shocks, form when the stars' powerful stellar winds, streams of matter flowing from the stars, slam into surrounding dense gas. The phenomenon is similar to that seen when a speeding boat pushes through water on a lake.
"We think we have found a new class of bright, high-velocity stellar interlopers," says astronomer Raghvendra Sahai of NASA's Jet Propulsion Laboratory in Pasadena, Calif., and leader of the Hubble study. "Finding these stars is a complete surprise because we were not looking for them. When I first saw the images, I said 'Wow. This is like a bullet speeding through the interstellar medium.' Hubble's sharp 'eye' reveals the structure and shape of these bow shocks."
The astronomers can only estimate the ages, masses, and velocities of these renegade stars. The stars appear to be young - just millions of years old. Their ages are based partly on their strong stellar winds.
Most stars produce powerful winds either when they are very young or very old. Only very massive stars greater than 10 times the Sun's mass have stellar winds throughout their lifetimes. But the objects observed by Hubble are not very massive, because they do not have glowing clouds of ionized gas around them. They are medium-sized stars that are a few to eight times more massive than the Sun. The stars are not old because the shapes of the nebulae around aging, dying stars are very different, and old stars are almost never found near dense interstellar clouds.
Depending on their distance from Earth, the bullet-nosed bow shocks could be 100 billion to a trillion miles wide (the equivalent of 17 to 170 solar system diameters, measured out to Neptune's orbit). The bow shocks indicate that the stars are traveling fast, more than 112,000 miles an hour (more than 180,000 kilometers an hour) with respect to the dense gas they are plowing through, which is roughly five times faster than typical young stars.
"The high-speed stars were likely kicked out of their homes, which were probably massive star clusters," Sahai says.
There are two possible ways this stellar expulsion could have happened. One way is if one star in a binary system exploded as a supernova and the partner got kicked out. Another scenario is a collision between two binary star systems or a binary system and a third star. One or more of these stars could have picked up energy from the interaction and escaped the cluster.
Assuming their youthful phase lasts only a million years and they are moving at roughly 112,000 miles an hour, the stars have traveled about 160 light-years.
Runaway stars have been seen before. The Infrared Astronomical Satellite (IRAS), which performed an all-sky infrared survey in 1983, spied a few similar-looking objects. The first observation of these objects was in the late 1980s. But those stars produced much larger bow shocks than the stars in the Hubble study, suggesting that they are more massive stars with more powerful stellar winds.
"The stars in our study are likely the lower-mass and/or lower-speed counterparts to the massive stars with bow shocks detected by IRAS," Sahai explains. "We think the massive runaway stars observed before were just the tip of the iceberg. The stars seen with Hubble may represent the bulk of the population, both because many more lower-mass stars inhabit the universe than higher-mass stars, and because a much larger number are subject to modest speed kicks."
Astronomers have not spotted many of these stellar interlopers before because they are hard to find. "You don't know where to look for them because you cannot predict where they will be," Sahai says. "So all of them have been found serendipitously, including the 14 stars we found with Hubble."
Sahai and his team used Hubble's Advanced Camera for Surveys to examine 35 objects that appeared as bright infrared sources in the IRAS archive. They were looking for long-lived pre-planetary nebulae, puffed-up aging stars on the verge of shedding most of their outer layers to become glowing planetary nebulae. Instead, the astronomers stumbled upon the runaway stars.
The team is planning follow-up studies to search for more interlopers, as well as study selected objects from this Hubble survey in greater detail to understand their effects on their environment.
"One of the questions that these very showy encounters raise is what effect they have on the clouds," says team member Mark Morris of the University of California, Los Angeles. "Is it an insignificant flash in the pan, or do the strong winds from these stars stir up the clouds and thereby slow down their evolution toward forming another generation of stars?"
Six Things Women Should Know About the Pap Test
January is Cervical Cancer Awareness Month and The University of Texas M. D. Anderson Cancer Center shares important information about the cervical cancer screening exam, the Pap test.
For many women, their annual Pap test is not something to look forward to; however, this test has the potential to make a huge difference in the lives of women everywhere. The Pap test detects cell changes, which may cause cervical cancer. If these cell changes are found and treated early, cervical cancer may be prevented.
Andrea Milbourne, M.D., associate professor in M. D. Anderson's Department of Gynecologic Oncology, explores six facts women should know about this important test.
1. Increased sexual activity equals increased need for a Pap test.
Increased sexual activity raises a woman¹s risk for acquiring the human papilloma virus (HPV). While HPV can be harmless, it also can cause cervical cancer by changing normal cells in the cervix.
"Because condoms do not provide 100 percent protection against HPV, women who are sexually active and not in a monogamous relationship need to be even more vigilant about following cervical cancer screening guidelines," Milbourne said.
2. The HPV vaccine is a supplement, not a replacement for the Pap test.
Getting the HPV vaccine, or encouraging young female family members to consider it, is a great first step toward cervical cancer prevention. That being said, the vaccine is in no way a substitute for the Pap test.
"The vaccine may give women a false sense of security," Milbourne said. "And because getting a Pap test is not what most women consider a favorite activity, getting the vaccine might cause them to procrastinate even more to make an appointment for their next Pap test."
Because the HPV vaccine does not protect against all types of HPV, or other sexually transmitted diseases, it cannot be the only method of cervical cancer prevention. Women also should remember that cervical cancer doesn¹t have many visible symptoms, which makes the Pap test significantly important in preventing cervical cancer.
3. Women should prepare for an upcoming Pap test.
Milbourne recommends a few tips to help women prepare for an upcoming test: * Avoid douching or using vaginal medicines, spermicidal foams, creams or jellies 48 hours before the test. * Do not have sexual intercourse 48 hours before the test. * Reschedule a Pap test appointment if an unexpected heavy menstrual flow occurs on the day of the exam.
"Lubricants, spermicides, douching and sexual activity can interfere with the interpretation of Pap test results, potentially leading to incorrectly interpreted results or the need for repeat tests," Milbourne said.
4. A woman is never too old to get her Pap test.
Of all the benefits that might come with growing older, skipping a regular Pap test for a sexually active woman over age 65 is not one of them.
As female life expectancy gets longer, many women continue to enjoy sexually active lives throughout their sixties and into their seventies.
"For women over age 65, cervical cancer is rare, but it does happen," Milbourne said. "If you are over age 65, sexually active and not in a monogamous relationship, you should continue your annual Pap test, as you are still susceptible to HPV, which can cause cervical cancer."
5. Women can afford a Pap test.
"Without health insurance or access to affordable health care, a Pap test can be costly," Milbourne said. "For women who can not afford a Pap test, there may be places in your community where you can get one for free."
For information on where to get a free or low-cost Pap test, call the National Cancer Institute¹s Cancer Information Service at 1-800-4-CANCER. Pap tests also are sometimes covered by Medicaid and are covered every two years by Medicare or every year for certain women at higher risk. For more information, call 1-800-MEDICARE.
6. Before the Pap test, cervical cancer was a leading cause of death in American women.
The American Cancer Society estimates that about 3,870 women died from cervical cancer in the United States during 2008. This number is low compared to annual statistics for other more common cancer types, such as breast or lung cancer, but what most people do not know is that cervical cancer was once one of the most common causes of cancer death in American women.
As the Pap test became a standard test for American women, doctors were able to find abnormal changes in the cervix before cancer developed. Between 1955 and 1992, the cervical cancer death rate declined by 74 percent.
"While the cervical cancer death rate continues to decline in the United States, women in countries where Pap tests are not as readily available or affordable still face the challenges, shared by American women more than 50 years ago," Milbourne said.
Cervical cancer is the second largest cause of female cancer deaths worldwide, according to the World Health Organization, with 288,000 deaths each year. About 510,000 cases of cervical cancer are reported each year nearly 80 percent are in developing countries.
For additional information, visit www.mdanderson.org/focused.
New Malaria Drug May Meet Resistance Says Expert
This year, the U.S. Food and Drug Administration is expected to approve the first malaria drug to contain artemisinin, a wormwood derivative from China that has proven effective for malaria in Africa and Asia. Although there are only about 1,500 reported cases of malaria treated in this country each year, this approval would also make the drug available to the military and to Americans planning to go abroad. However, worldwide malaria is still one of the most serious infectious diseases, affecting 2 to 3 billion people, with up to two million deaths annually.
The drug, named Coartem, is made by the Swiss company Novartis. It combines artemether, an artemesinin derivative, with lumefantrine, a drug developed by Chinese scientists, which does not kill parasites as quickly but lingers in the blood a while longer. By mopping up parasites that artemisinin misses, lumefantrine helps prevent resistance that would defeat the drug, as has occurred with other therapies like chloroquine.
According to University of Pennsylvania pharmacologist Doron Greenbaum, Ph.D., although the exact mechanism by which artemisinin kills parasites is still open to considerable debate, the drug likely acts against one or more protein targets that may make it susceptible to resistance that has developed to most other drugs. Drug resistance to artemisinin has already been shown to occur in the laboratory, and reports have already surfaced about potential resistance in malaria endemic regions like southeast Asia. Thus the potential success of Coartem treatment for malaria should be greeted with cautious optimism knowing that resistance is likely to arise and that other new drugs will need to be developed quickly.
Dr. Greenbaum recently reported that small molecule defensin-mimetic compounds discovered by Radnor, Penn.-based biopharmaceutical company PolyMedix, irreversibly kill P. falciparum while sparing human red blood cells. Plasmodium species are responsible for the nearly five hundred million cases of malaria worldwide and as many as two million deaths, most of them in children. As with antimicrobial agents, first-line malaria agents are losing effectiveness due to development of resistance to drugs by the target organisms.
Dr. Greenbaum demonstrated that PolyMedix¹s compounds kill P. falciparum irreversibly, meaning the cells do not recover when the agent is depleted. Irreversible killing distinguishes a ³cidal,² or true killing mechanism, from a ³static² mechanism that holds the infectious agent at bay while the body¹s immune system fights off the infection. ³If we treat for ten hours and remove the compound, the parasites never recover,² notes Dr. Greenbaum. Many antimicrobial and antifungal drugs are of the static variety.
PolyMedix antibiotics are small-molecule non-peptide mimetics of natural host defense peptides that higher animals use to fight infections. In humans these molecules, known as defensins, are about thirty amino acids in length. Although structurally quite dissimilar, defensins and PolyMedix¹s compounds share a common characteristic that is responsible for their anti-infective activity. Both molecules are facially amphiphilic, meaning they possess several polar, or charged chemical groups on one side of the molecule, and hydrophobic groups on the other side. They are believed to work by inserting themselves inside the lipid bilayers of cells that are deficient in cholesterol, thereby causing the cells to rupture and die. Therefore these molecules kill pathogens by targeting membranes rather than proteins. Dr. Greenbaum hypothesizes that this mechanism is employed against both bacteria and Plasmodium.
³As far as we know, the PolyMedix defensin-mimetics are the only anti-infectives with such a biophysical mechanism of action, directly targeting the membrane, whether bacterial, fungal, or parasitic," says Dr. Greenbaum. ³This makes resistance unlikely to develop. Any biochemical/protein-based mechanism of action is susceptible to resistance via efflux or target mutation."
The complex lifecycle of P. falciparum makes malaria difficult to treat once it is established. The organism typically enters the body through a mosquito bite, soon takes residence in the liver, and then migrates to red blood cells. It is the last stage that gives rise to the chronic disease known as malaria. During their lifecycle the organisms take on several distinct morphologic and biological forms. PolyMedix¹s defensin-mimetics show very high killing efficacy against all stages of red cell infection. The next step is to see if the compounds can clear infection in a mouse model, in the liver phase, as well as the red cell stage.
PolyMedix's lead defensin-mimetic antibiotic compound, PMX-30063, is currently in human clinical testing, and is intended to be developed as a broad anti-Staph agent. The first Phase I clinical results with PMX-30063 were announced in December 2008.
For more information, log onto http://www.polymedix.com.
Stroke Belt: Deaths Tied to Non-Traditional Risk Factors
Southerners die from stroke more than in any other U.S. region, but exactly why that happens is unknown. A new report by researchers at the University of Alabama at Birmingham (UAB) and the University of Vermont underscores that geographic and racial differences are not the sole reasons behind the South's higher stroke death rate.
The data is from UAB's Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, which has enrolled more than 30,200 U.S. participants. The study confirms a greater-than 40 percent higher stroke death rate in eight southeastern states known as the Stroke Belt Alabama, Arkansas, Georgia, Louisiana, Mississippi, North and South Carolina and Tennessee.
After factoring in age, race and sex-related factors, the predicted stroke risk was only slightly higher in Stoke Belt states compared to other regions (10.7 percent versus 10.1 percent), said George Howard, Dr.PH., professor of biostatistics in UAB's School of Public Health and a REGARDS principal. That risk was calculated using nine known risk factors common to stroke screening.
"We found geographic and racial differences are useful in predicting stroke risk, but they only explain less than half the picture. Something else is happening," Howard said. "It could be exposure to allergens in the home, it could be micronutrients in drinking water or it could be other factors considered non-traditional because they don't fall into the list of nine factors commonly used to predict stroke risk."
The findings are reported in the Annals of Neurology.
All minority groups, including Native Americans, Hispanics and African-Americans, face a significantly higher risk for stroke and death from stroke compared to whites, and research is focused on exactly why that is, said Mary Cushman, M.D., of the University of Vermont, the study¹s lead author. Continued analysis of REGARDS data and follow-up study will determine other stroke risk factors and their significance.
One detail that emerged in the Annals of Neurology study is that the prevalence of diabetes and hypertension was up to five percentage points higher in the Southeast. That means interventions to reduce geographic disparities in diabetes and hypertension including boosting diabetes screening rates and follow-up care could also reduce geographic disparities in stroke death, Howard said.
REGARDS already has spawned more than 50 accompanying research reports. The study is a research partnership that includes UAB's Departments of Epidemiology, Biostatistics and Preventive Medicine, UAB's Center for Aging and the Center for the Study of Community Health, the University of Vermont in Burlington, the University of Arkansas for Medical Sciences in Little Rock, the University of Cincinnati, Indiana University in Indianapolis, the Alabama Neurological Institute in Birmingham, the Medical University of South Carolina in Charleston and Wake Forest University School of Medicine in Winston-Salem, N.C.
Friday, February 20, 2009
Replacing Your Total Hip Replacement
Thousands of patients undergo total hip replacement surgery each year in order to help alleviate pain associated with debilitating hip disease and other related hip problems, but there is limited information regarding why many of those hip replacements fail.
So researchers analyzed data from about fifty thousand patients who had to have their hip replacements revised. Based on new diagnosis and procedure codes specifically for hip replacement revision, they were able to identify certain trends.
Researchers found the most common reasons for patients needing subsequent hip replacement surgery include:
* Dislocation of the implant
* Loosening of the implant
* Infection such as staph infections either around the time of surgery or later through the bloodstream
“The reason why this study is important is because up until now it has been believed that the most common reason why hip replacements fail is because the bearing surface wears out. Although our study confirmed that problems related to bearing surface wear do cause hip replacements to fail, we found that other problems including dislocation, implant loosening, and infection - may be even more common causes of hip replacement failure,” explains Bozic. “This suggests that in addition to research aimed at developing better implants, we also need to direct new research efforts to improve care in those three areas.”
Bozic also noted that there are other benefits to having this type of information. “One of our goals is to use these new diagnoses and procedure codes related to hip replacement to help create a national joint replacement registry which is what has been done in many other developed countries. Every patient who has a joint replacement gets entered into a national database and is tracked over time. It allows us to know specifically what happened to their hip replacement and when.”
Results from the study indicate there are things within the surgeon’s control such as surgical technique and the way the implant is installed that physicians should be thinking about as potential causes for failure as opposed to just design factors related to the implants. “Although we now have a better understanding as to why hip replacements fail, we need to do more detailed studies to find out the reasons why dislocation and infection are common causes of hip replacement failure,” said Bozic.
Thursday, January 22, 2009
Ancient African Exodus Mostly Involved Men, Geneticists Find
Newswise — Modern humans left Africa over 60,000 years ago in a migration that many believe was responsible for nearly all of the human population that exist outside Africa today.
Now, researchers have revealed that men and women weren’t equal partners in that exodus. By tracing variations in the X chromosome and in the non-sex chromosomes, the researchers found evidence that men probably outnumbered women in that migration. The scientists expect that their method of comparing X chromosomes with the other non-gender specific chromosomes will be a powerful tool for future historical and anthropological studies, since it can illuminate differences in female and male populations that were inaccessible to previous methods.
While the researchers cannot say for sure why more men than women participated in the dispersion from Africa—or how natural selection might also contribute to these genetic patterns—the study’s lead author, Alon Keinan, notes that these findings are “in line with what anthropologists have taught us about hunter-gatherer populations, in which short distance migration is primarily by women and long distance migration primarily by men.”
These findings are published in Nature Genetics.
Wednesday, January 21, 2009
Scientists Discover an Ancient Odor-Detecting Mechanism in Insects
Newly discovered receptors in the nose of a common insect unearths one of the most ancient mechanisms that organisms have evolved to smell. Ionotropic glutamate receptors, proteins that reside deep in the brain at the synapses, grab glutamate molecules and quickly relay messages from one nerve cell to the next, helping animals learn, move and remember. But insects do not relegate these receptors to the depths of the brain. They also put them to use elsewhere: in the nose.
"On the surface it's a completely absurd idea," says Leslie B. Vosshall, head of the Laboratory of Neurogenetics and Behavior at Rockafeller University. "We know what these proteins do; they sit at the synapse and mediate fast neuronal communication. So the idea that the fly has massively expanded the number of these receptors and positioned them to interact with small molecules in the air seems very strange. But if you think about it, it makes sense. The process is the same, but rather than grabbing small molecules at the synapse, they're grabbing small molecules from the air."The project began two years ago, when Vosshall and Richard Benton, then a postdoc in her lab, noticed a group of six ionotropic glutamate receptor genes while sifting through the fly genome. Although this group was recognized 10 years ago, ever since the genome was sequenced, the genes did not have a known function, in part because it was assumed they must be similar to any other ionotropic glutamate receptor deep in the fly brain. But to Vosshall and Benton, who is now at the Center for Integrative Genomics in Lausanne, Switzerland, that didn't matter.
Vosshall and her team wondered whether these receptors could in fact represent the "missing" receptors thought to exist in the fly's "nose" -- its two antennae. Each antenna is divided into three types of smell neurons. Scientists have characterized the receptors that detect odors in two of these types but those receptors were mysteriously absent in the third, a swath of territory known as the coeloconic sensilla. "It has been shown that cells in the coeloconic sensilla detect odors," Vosshall says. "It's just that we didn't know how they did it."
The team showed that these receptors, which the Vosshall lab named ionotropic receptors, do in fact explain how cells in coeloconic sensilla detect odors. First, they showed that they are expressed in complex combinatorial patterns at the sensory end of olfactory neurons where they have access to and can scan the outside world for odors. They then showed that when these receptors are expressed in the cells in the coeloconic sensilla, the cells respond to odors. Finally, the researchers showed that when they plucked a receptor -- say one that detects an odor that resembles a mix of grass and honey -- out of its native cell and genetically embedded it in a different cell, the new cell would now detect that odor.
Although it is still unclear why insects have developed two sets of chemosensory receptors -- olfactory receptors and ionotropic receptors -- the work raises questions regarding their evolutionary origin. Ten years ago, researchers at New York University revealed that plants, which detect soil nutrients and chemicals in the air, also express glutamate receptors, suggesting that the ancestral origin of glutamate receptors may have been to detect small molecules in the air, rather than small molecules in the brain.
"In a way, these receptors were very well hidden because everyone assumed that they were extra glutamate receptors that were unlikely to be of interest," explains Vosshall. "All we did to find them was searched for a gene family of unknown function -- and left our preconceived notions aside."
This work was funded in part by grants from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative and the National Institutes of Health. read the full article...
Vets and Depression: Return from War to Fight New Battle
Newswise — When Lamont Christian returned from war, he often felt angry, afraid and unworthy. Years later, Christian found himself living in a homeless shelter, a sign that time had not healed his emotional wounds.
He went to the VA Ann Arbor Healthcare System for help, and there, he learned the root of his problems: he was suffering from depression, post-traumatic stress disorder and anger management problems. Now, he wants others to learn from his experience.
"If I had a message to give to veterans who are coming out of the military now or even veterans who have been out for a long period of time, it's that nothing is going to happen in your life unless you go and get the help you need," he says.
Christian is a veteran of Vietnam, but his experience holds true for soldiers returning from current battlegrounds as well.Nearly a third of veterans who are treated at Veterans Affairs health care centers have significant depressive symptoms, and about 13 percent have clinically diagnosed depression, says Marcia Valenstein, M.D., clinical psychiatrist with the VA Ann Arbor Healthcare System and associate professor of psychiatry with the University of Michigan Health System.
Depression is a "very potent" risk factor for suicide among people receiving treatment for depression at the VA, she notes, with a suicide rate that is three times higher than that of the overall VA patient population.
Such high rates led Valenstein and her colleagues to study the best time to provide intensive interventions to veterans with depression to prevent suicide. In a study just published by the Journal of Affective Disorders, the researchers found that veterans with depression were at highest risk for suicide in the 12 weeks after they were hospitalized for psychiatric conditions.
"This finding highlights the need for very close follow-up for patients who are discharged from our inpatient services because this is a particularly vulnerable time for them," says Valenstein, a core investigator with the Serious Mental Illness Treatment Research and Evaluation Center at the VA Ann Arbor Healthcare System.
Current government recommendations have focused on providing intensive follow up for patients following all new antidepressant starts. More attention needs to be paid to the highest-risk periods that follow psychiatric hospitalization, Valenstein says. "Health systems with limited resources should focus their efforts on this time period to have the greatest impact on suicide prevention."
The Department of Veterans Affairs has made mental health issues a priority, Valenstein notes. VA health centers have received more than $300 million for expansion of suicide prevention and other mental health services from the Veterans Health Administration.
Note: The views expressed in the study are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. read the full article...
